RNAi therapeutics: Principles, prospects and challenges

被引:672
作者
Aagaard, Lars [1 ]
Rossi, John J. [1 ]
机构
[1] City Hope Natl Med Ctr, Beckman Res Inst, Div Mol Biol, Duarte, CA 91010 USA
关键词
siRNA; shRNA; RNAi; RNA interference; antisense; miRNA; RISC;
D O I
10.1016/j.addr.2007.03.005
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
RNA interference (RNAi) was discovered less than a decade ago and already there are human clinical trials in progress or planned. A major advantage of RNAi versus other antisense based approaches for therapeutic applications is that it utilizes cellular machinery that efficiently allows targeting of complementary transcripts, often resulting in highly potent down-regulation of gene expression. Despite the excitement about this remarkable biological process for sequence specific gene regulation, there are a number of hurdles and concerns that must be overcome prior to making RNAi a real therapeutic modality, which include off-target effects, triggering of type I interferon responses, and effective delivery in vivo. This review discusses mechanistic aspects of RNAi, the potential problem areas and solutions and therapeutic applications. It is anticipated that RNAi will be a major therapeutic modality within the next several years, and clearly warrants intense investigation to fully understand the mechanisms involved. (C) 2007 Elsevier B.V. All rights reserved.
引用
收藏
页码:75 / 86
页数:12
相关论文
共 116 条
  • [51] Interference of hepatitis C virus RNA replication by short interfering RNAs
    Kapadia, SB
    Brideau-Andersen, A
    Chisari, FV
    [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) : 2014 - 2018
  • [52] Khvorova A, 2003, CELL, V115, P209, DOI 10.1016/S0092-8674(03)00801-8
  • [53] Interferon induction by siRNAs and ssRNAs synthesized by phage polymerase
    Kim, DH
    Longo, M
    Han, Y
    Lundberg, P
    Cantin, E
    Rossi, JJ
    [J]. NATURE BIOTECHNOLOGY, 2004, 22 (03) : 321 - 325
  • [54] Synthetic dsRNA Dicer substrates enhance RNAi potency and efficacy
    Kim, DH
    Behlke, MA
    Rose, SD
    Chang, MS
    Choi, S
    Rossi, JJ
    [J]. NATURE BIOTECHNOLOGY, 2005, 23 (02) : 222 - 226
  • [55] Subgenomic replicon derived from a cell line infected with the hepatitis C virus
    Kishine, H
    Sugiyama, K
    Hijikata, M
    Kato, N
    Takahashi, H
    Noshi, T
    Nio, Y
    Hosaka, M
    Miyanari, Y
    Shimotohno, K
    [J]. BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2002, 293 (03) : 993 - 999
  • [56] Enhancement of hepatitis C virus RNA replication by cell culture-adaptive mutations
    Krieger, N
    Lohmann, V
    Bartenschlager, R
    [J]. JOURNAL OF VIROLOGY, 2001, 75 (10) : 4614 - 4624
  • [57] Silencing of microRNAs in vivo with 'antagomirs'
    Krützfeldt, J
    Rajewsky, N
    Braich, R
    Rajeev, KG
    Tuschl, T
    Manoharan, M
    Stoffel, M
    [J]. NATURE, 2005, 438 (7068) : 685 - 689
  • [58] Expression of small interfering RNAs targeted against HIV-1 rev transcripts in human cells
    Lee, NS
    Dohjima, T
    Bauer, G
    Li, HT
    Li, MJ
    Ehsani, A
    Salvaterra, P
    Rossi, J
    [J]. NATURE BIOTECHNOLOGY, 2002, 20 (05) : 500 - 505
  • [59] The nuclear RNase III Drosha initiates microRNA processing
    Lee, Y
    Ahn, C
    Han, JJ
    Choi, H
    Kim, J
    Yim, J
    Lee, J
    Provost, P
    Rådmark, O
    Kim, S
    Kim, VN
    [J]. NATURE, 2003, 425 (6956) : 415 - 419
  • [60] Prediction of mammalian microRNA targets
    Lewis, BP
    Shih, IH
    Jones-Rhoades, MW
    Bartel, DP
    Burge, CB
    [J]. CELL, 2003, 115 (07) : 787 - 798